Background: The suppression of the pituitary secretion of gonadotropins and subsequently the suppression of gonadal sex steroid production is the main therapeutic goal in the treatment of children with central precocious puberty. We investigated the efficacy of a depot formulation of the GnRH agonist leuprorelin for subcutaneous injection in a prospective multicentric study according to the guidelines of Good Clinical Practice.  
